Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Garleb, K. A.; Snook, J. T.; Marcon, M. J.; Wolf, B. W.; Johnson, W. A. (2011)
Publisher: Microbial Ecology in Health and Disease
Journal: Microbial Ecology in Health and Disease
Languages: English
Types: Article
Fructooligosaccharides (FOS) are an ingredient which may be incorporated into enteral products. However, prior to the addition of FOS to such products, studies related to the identification of any negative side effects associated with their consumption must be conducted. This double-blind study was conducted to assess the effect of FOS-containing enteral formulas on subjective tolerance factors, serum chemistry profiles and faecal bifidobacteria in healthy male college students. Three dietary formulas were investigated including a low residue polymeric formula (A), A+5 g FOS/L (B), and A+10 g FOS/L (C). Twenty-seven students (nine subjects/treatment) were randomly assigned to one of the dietary treatments. Subjects consumed the specified formula as their sole source of nutrition for 14 d. The amount of formula consumed by each subject was recorded daily and caloric intakes were adjusted to maintain the subjects' initial body weight. Faecal and blood samples were collected at baseline (day 0) and day 14. Using a daily questionnaire, subjects were asked to report the frequency of the following gastrointestinal symptoms: nausea, cramping, diarrhoea, distention, flatus, vomiting and regurgitation. Daily consumptions of FOS (g ± SEM) were 0 ± 0, 15 ± 1·0, and 31 ± 2·6 for dietary treatments A, B, and C, respectively. Tolerance to all dietary treatments was good. Few complaints of nausea, cramping, diarrhoea, marked distention, vomiting or regurgitation were reported regardless of treatment. More complaints of flatus and slight distention were reported with the FOS-containing diets, particularly diet C, compared with A. These symptoms were mild and subsided as the study progressed. No clinically significant differences in serum chemistries were detected as a function of formula intake. Faecal microbiota changes, as a function of diet, were detected. Specifically, the ingestion of diets B and C resulted in greater (P<0.001) bifidobacteria levels in faeces compared with A on day 14. Results indicate that fructooligosaccharides do not compromise serum chemistries, are well tolerated particularly at an intake of 15 g/d, and are a bifidogenic factor in low residue polymeric formulas.Keywords: fructooligosaccharide, enteral formula, bifidobacteria, tolerance.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Becker R, Lorenz K, Saunders RM. (1977). Saccharides of maturing triticale, wheat and rye.
    • Journal of Agricultural Food Chemistry 25, 1115- 1118.
    • Biavati B, Sgorbati B, Scardovi V. (1992). The genus bifidobacterium. In: Balows A, Triipes HG, Dworkin M, Harder W, Schleifer KH (eds) The Prokaryotes: A Handbook on the Biology of Bacteria, 2nd edn. Springer-Verlag, pp. 816-833.
    • Briet F, Achour L, Flourit B, Beaugerie L, Pellier P, Franchisser C, Bornet F, Rambaud J-C. (1995).
    • Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. European Journal Clinical Nutrition 49, 501-507.
    • Clevenger MA, Turnbull D, Inoue H, Enomoto M, Allen J, Henderson L, Jones E. (1988). Toxicological evaluation of neosugar: Genotoxicity, carcinogenicity, and chronic toxicity. Journal of the American College of Toxicology 7 , 643-662.
    • 5. Darbyshire B, Henry RJ. (1981). Differences in fructan content and synthesis in some Alliwn species. New Phytologist 82, 249-256.
    • 6. Hata Y, Hara T, Oikawa T, Yamamoto M, Hirose N, Nagashima T, Torihama N, Nakajima K, Watabe A, Yamashita M. (1983). Effects of fructooligosaccharides (Neosugar) on hyperlipidemia. Geriatric Medicine 21, 156-167.
    • 7. Hata Y , Nakajima K. (1985). Studies on relationship between intake of fructooligosaccharides and abdominal symptoms-Estimation of maximum non-effective dose and 50% laxative effective dose. Geriatric Medicine 23, 8 17-828.
    • 8. Hidaka H, Eida T, Takizawa T, Tokunaga T, Tashiro Y . (1986). Effects of fructooligosaccharides on intestinal flora and human health. Bifidobacteria and Microflora 5, 37-50.
    • 9. Hidaka H, Hirayama M, Yamada K. (1991). Fructooligosaccharide enzymatic preparation and biofunction. Journal of Carbohydrate Chemistry 10, 509-522.
    • 10. Homma N. (1988). Bifidobacteria as a resistance factor in human beings. Bifidobacteria and MicroJora 7, 3 5 4 3 .
    • 11. Hosoya N, Dhorranintra B, Hidaka H. (1988). Utilization of [U-I4C] fructooligosaccharides in man as energy resources. Journal of Clinical Biochemistry and Nutrition 5, 67-74.
    • 12. May T, Mackie RI, Fahey G C Jr, Cremin JC, Garleb KA.(1994). Effect of fiber source on shortchain fatty acid production and on the growth and toxin production by Clostririitrm dificile. Scandinavian Journal of Gastroenterology 19, 9 16- 922.
    • 13. Mitsuoka T. (1982). Recent trends in research on intestinal flora. Bifdobacteria and Microflora 1, 3-24.
    • 14. Mitsuoko T , Hidaka H, Eida T. (1987). Effect of fructo-oligosaccharides on intestinal microflora. L)ie Nahrung 31, 427-436.
    • 15. Mitsuoko T, Kaneuchi C. (1977). Ecology of the bifidobacteria. American Journal of Clinical Nutrition 30, 1799-1810.
    • 16. R4odler HW, McKellar RC, Yaguchi M. (1990). Bifidobacteria and bifidogenic factors. Canadian Institute of Food Science and Technology Journal 23, 29-41.
    • 17. Munoa FJ, Pares R. (1988). Selective medium for isolation and enumeration of Bifidobacteriirm spp. Applied and Environmental Microbiology 54, 1715- 1718.
    • 18. Nash P, Krenz M. (1991). Culture media. In: Balows A (ed) Manual of Clinical Microbiokyy, 5th edn. American Society of Microbict!opy, Washington, DC, pp. 1226-1288.
    • 19. Oku T, Tokunaga T, Hosoya N. (1984). idondigestibility of a new sweetener, “Neosugar”, in the rat. Journal of Nutrition 114, 1574-1581.
    • 20. Palmquist DL, Conrad HR. (1978). High fat rations for dairy cows. Effects on feed intake, milk and fat production and plasma metabolites. Journal of Dairy Science 61, 890-901.
    • 21. Scardovi V. (1986). Bifidobacterium. In: Sneath PH, Mair NS, Sharpe ME, Holt J (eds) Bergey's Manual of Systemic Bacteriology 1st edn, Vol 11, Williams and Wilkins Publishers, Baltimore, MD, pp. 1418-1434.
    • 22. Shiomi N, Izawa M. (1980). Purification and characterization of sucrose-sucrose I-fructosyltransferase from the roots of asparagus. Agriculturd and Biological Chemistry 44, 603-614.
    • 23. Stone-Dorshow T, Levitt MD. (1987). Gaseous response to ingestion of a poorly absorbed fructooligosaccharide sweetener. American Journal of Clinical Nutrition 46, 61-65.
    • 24. Tissier H. (1900) Recherches sur la flore intestinale des noirrrissons (etat normal et patliologique) ,These de medecine de I'Universite de Paris.
    • 25. Tokunaga T, Oku T, Hosoya N. (1986). Influence of chronic intake of new sweetener fructooligosaccharide (Neosugar) on growth and gastrointestinal function of the rat. Journal of Nutritional Science and Vitaminology 32, 111-121.
    • 26. Tokunaga T, Oku T, Hosoya N. (1989). Utilization and excretion of a new sweetener, fructooligosaccharide (Neosugar), in rats. Jotrrnal of Nutrition 119, 553-559.
    • 27. Williams CH, Witherly SA, Buddington RK. (1994). Influence of dietary neosugar on selected bacterial groups of the human faecal microbiota. Microbial Ecology in Health and Disease 7, 91-97.
    • 28. Wolf BW, Titgemeyer EC, Fahey GC, Garleb KA. (1994). Fermentability of selected oligosaccharides. The FASEB Journal 8, A186.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from